Renal and Non-renal Excretion — MCQs
A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?
Which of the following statements about the biodisposition of penicillins and cephalosporins is NOT accurate?
Which of the following is the MOST important factor determining whether a substance can be filtered at the glomerulus?
A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
Free water clearance is decreased by?
Major mechanism of transport of drugs across biological membranes is:
Bile salts undergo conjugation for enhanced solubility:
In which of the following conditions is digoxin most likely to accumulate to toxic levels?
Which of the following is the primary mechanism that drives sodium reabsorption in the proximal tubule?
Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
Renal and Non-renal Excretion Indian Medical PG Practice Questions and MCQs
Question 1: A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 ng/mL. The plasma therapeutic range is 1-2 ng/mL. If the half-life of digoxin is 40 hours, how long should one wait before resuming the treatment?
- A. 120 hours
- B. 140-180 hours
- C. 1 half-life (40 hours)
- D. 80 hours (Correct Answer)
Explanation: ***80 hours (2 half-lives)***- Current digoxin level is **4 ng/mL**, which is **twice the upper therapeutic limit** (2 ng/mL), causing toxicity with nausea and vomiting [1]- After **1 half-life (40 hours)**: concentration reduces to 2 ng/mL (upper therapeutic limit) [2]- After **2 half-lives (80 hours)**: concentration reduces to 1 ng/mL (mid-therapeutic range) [2]- **Clinical rationale**: While 2 ng/mL is technically within range, waiting for 2 half-lives ensures the level is comfortably in the **middle of the therapeutic window** (1 ng/mL), providing a **safer margin** before resuming treatment in a patient who just experienced toxicity- This conservative approach minimizes risk of recurrent toxicity, especially important given the patient's recent symptoms at 4 ng/mL*1 half-life (40 hours)*- After 1 half-life, digoxin level would be 2 ng/mL, which is at the **upper limit** of the therapeutic range- While technically within the therapeutic range, this leaves **minimal safety margin** in a patient who just experienced toxicity- Starting treatment immediately at this level carries higher risk of recurrent side effects*120 hours (3 half-lives)*- After 3 half-lives, the concentration would be **0.5 ng/mL**, which is **below the therapeutic range** (1-2 ng/mL)- This is overly conservative and would **unnecessarily delay** resumption of essential cardiac medication- Could lead to inadequate control of the underlying condition (heart failure or atrial fibrillation)*140-180 hours (3.5-4.5 half-lives)*- This would reduce digoxin to **0.25-0.35 ng/mL**, well below therapeutic levels- This **excessive delay** is not clinically justified and could worsen the patient's cardiac condition- No standard protocol recommends waiting this long before resuming digoxin therapy
Question 2: Which of the following statements about the biodisposition of penicillins and cephalosporins is NOT accurate?
- A. Procaine penicillin G is used for intramuscular injection
- B. Nafcillin and ceftriaxone are eliminated mainly by biliary secretion
- C. Oral bioavailability is affected by lability to gastric acid
- D. Renal tubular reabsorption of beta-lactams is inhibited by probenecid (Correct Answer)
Explanation: ***Renal tubular reabsorption of beta-lactams is inhibited by probenecid*** - Probenecid inhibits the **active tubular secretion** of beta-lactam antibiotics, not their reabsorption, thereby increasing their half-life and maintaining higher plasma concentrations [3]. - This interaction is clinically useful for prolonging the antibacterial effect of penicillins and cephalosporins. *Oral bioavailability is affected by lability to gastric acid* - Many early penicillins, such as **penicillin G**, are highly susceptible to degradation by stomach acid, leading to poor oral bioavailability [2]. - This necessitates their administration via intravenous or intramuscular routes, or the development of **acid-stable analogs** like penicillin V [2]. *Procaine penicillin G is used for intramuscular injection* - **Procaine penicillin G** is formulated for intramuscular injection to create a **depot effect**, allowing for slow absorption and prolonged therapeutic plasma concentrations. - The procaine component also acts as a **local anesthetic**, reducing the pain associated with a large-volume intramuscular injection [1]. *Nafcillin and ceftriaxone are eliminated mainly by biliary secretion* - **Nafcillin** and **ceftriaxone** are indeed notable among beta-lactam antibiotics for their significant elimination through the biliary tract. - This route of excretion makes them particularly useful in patients with **renal impairment**, as their elimination is less dependent on kidney function.
Question 3: Which of the following is the MOST important factor determining whether a substance can be filtered at the glomerulus?
- A. Lipid solubility of the substance
- B. Molecular weight of the substance (Correct Answer)
- C. Binding capacity to albumin
- D. None of the options
Explanation: ***Molecular weight of the substance*** - The **glomerular filtration barrier** acts as a size-selective filter, generally permeable to substances with a molecular weight less than 5,000-10,000 Daltons - Larger molecules are typically restricted from filtration due to the **size exclusion** property of the glomerular basement membrane and podocyte slit diaphragms - This is the **primary determinant** of whether a substance can be filtered at all, making it the most important factor among the given options *Lipid solubility of the substance* - **Lipid solubility** is more relevant for reabsorption and secretion in the renal tubules, particularly for passive diffusion across tubular cell membranes - It has minimal direct influence on the initial filtration process at the glomerulus, which is primarily a **pressure-driven, size- and charge-selective ultrafiltration** process - The glomerular capillary wall is not a lipid membrane barrier for the filtration process *Binding capacity to albumin* - Substances bound to **large plasma proteins** like albumin (molecular weight ~67,000 Daltons) cannot pass through the glomerular filtration barrier - While important for determining the *free, filterable fraction* of a substance in plasma, the binding itself is secondary to the fundamental molecular weight/size restriction - Only the **free (unbound) fraction** of a substance is available for filtration, and whether it filters depends primarily on its molecular weight *None of the options* - This option is incorrect because **molecular weight** is indeed the most critical factor among the given options for determining whether a substance can be filtered at the glomerulus
Question 4: A 70 kg man was given a drug with a dose of 100 mg/kg body weight, twice daily. The half-life (t1/2) is 10 hours, the plasma concentration is 1.9 mg/mL, and the clearance is unknown. What is the clearance of this drug?
- A. 20 liter/hr
- B. K is 0.0693
- C. 0.22 L/hr (Correct Answer)
- D. 0.02 L/hr
Explanation: ***0.22 L/hr*** - To calculate clearance at steady state, we use the formula: **Clearance (Cl) = Dose Rate / Css** (steady-state plasma concentration). - **Dose rate calculation**: 100 mg/kg × 70 kg × 2 doses/day = 14,000 mg/day = 583.33 mg/hr - **Converting plasma concentration**: 1.9 mg/mL = 1900 mg/L - **Clearance calculation**: Cl = 583.33 mg/hr ÷ 1900 mg/L = **0.307 L/hr** - **Note**: The calculated value (0.307 L/hr) does not exactly match any option. The marked answer (0.22 L/hr) is the closest approximation among the given choices. This discrepancy may arise from rounding in the original question parameters or implicit assumptions about bioavailability/volume of distribution. *0.02 L/hr* - This value is approximately 15 times lower than the calculated clearance. - Such low clearance would result in much higher plasma concentrations or require significantly lower dosing. *20 liter/hr* - This clearance is approximately 65 times higher than calculated, representing an unrealistically high value for this scenario. - Such high clearance would result in very low plasma concentrations unless extremely high doses were administered. *K is 0.0693* - This represents the **elimination rate constant (k)**, calculated as k = 0.693/t1/2 = 0.693/10 hr = 0.0693 hr⁻¹. - While mathematically correct for k, the question specifically asks for **clearance**, not the elimination rate constant. - Clearance is related to k by: Cl = k × Vd (volume of distribution).
Question 5: Free water clearance is decreased by?
- A. Furosemide
- B. Vinblastine
- C. Vincristine
- D. Chlorpropamide (Correct Answer)
Explanation: ***Chlorpropamide*** - **Chlorpropamide** is a sulfonylurea oral hypoglycemic agent that is a **classic and well-documented cause of SIADH (Syndrome of Inappropriate Antidiuretic Hormone)**. - **SIADH** leads to increased ADH secretion, causing increased water reabsorption in the collecting ducts and thus **decreased free water clearance**. - Among the options listed, chlorpropamide is the **prototypical drug** associated with drug-induced SIADH in pharmacology teaching. *Furosemide* - **Furosemide** is a loop diuretic that inhibits the reabsorption of sodium and chloride in the **loop of Henle**. - This disrupts the medullary concentration gradient and leads to increased excretion of water and electrolytes, thereby **increasing free water clearance**. *Vinblastine* - **Vinblastine** is a vinca alkaloid chemotherapeutic agent primarily used in cancer treatment. - It does not significantly affect renal water handling or ADH secretion and does **not typically cause SIADH**. *Vincristine* - **Vincristine** is another vinca alkaloid chemotherapy drug that **can also cause SIADH** and decrease free water clearance. - However, in the context of standard pharmacology teaching and board examinations, **chlorpropamide** is the more classical example emphasized for drug-induced SIADH and decreased free water clearance. - Vincristine is primarily known for its **neurotoxicity** as a major side effect.
Question 6: Major mechanism of transport of drugs across biological membranes is:
- A. Passive diffusion (Correct Answer)
- B. Facilitated diffusion
- C. Active transport
- D. Endocytosis
Explanation: ***Passive diffusion*** - This is the **most common mechanism** for drug transport across biological membranes, especially for **lipid-soluble** drugs. - It occurs down a **concentration gradient** and does not require energy or carrier proteins. *Facilitated diffusion* - This process requires **carrier proteins** to move drugs across membranes, but it still occurs down a **concentration gradient** and does not consume energy directly. - It handles substances that are **too large or too polar** to cross by passive diffusion, but it is not the primary mechanism for most drugs. *Active transport* - This mechanism uses **carrier proteins** and **expends energy (ATP)** to move drugs against their **concentration gradient**. - It is important for the transport of specific drugs, but it is not the predominant mode for the majority of drug molecules. *Endocytosis* - This involves the **engulfment of large molecules** or particles by the cell membrane, forming vesicles. - It is a less common mechanism for drug absorption, primarily used for **very large molecules** like proteins or nanoparticles.
Question 7: Bile salts undergo conjugation for enhanced solubility:
- A. After conjugation with derived proteins
- B. After conjugation with lysine
- C. After conjugation with taurine and glycine (Correct Answer)
- D. After conjugation with betaglucuronic acid
Explanation: ***After conjugation with taurine and glycine*** - This statement accurately describes the most common conjugation pathway for bile acids, increasing their **amphipathic properties** and solubility. - Conjugation with these amino acids forms **bile salts** (e.g., glycocholate, taurocholate), which are essential for **micelle formation** and fat digestion. - This is the primary mechanism by which bile acids become bile salts with enhanced solubility. *After conjugation with betaglucuronic acid* - While bile acids do undergo conjugation for increased solubility, they are primarily conjugated with glycine or taurine, not beta-glucuronic acid. - Conjugation with beta-glucuronic acid is a common detoxification pathway for many xenobiotics and bilirubin, but not the primary method for bile acids. *After conjugation with derived proteins* - Bile salts are primarily steroid derivatives and are not conjugated with derived proteins. - The purpose of conjugation is to increase hydrophilicity, which proteins would not achieve in this context. *After conjugation with lysine* - Lysine is an amino acid but is not involved in the conjugation of bile acids. - Bile acid conjugation specifically uses the amino acids glycine and taurine.
Question 8: In which of the following conditions is digoxin most likely to accumulate to toxic levels?
- A. Renal insufficiency (Correct Answer)
- B. Chronic hepatitis
- C. Advanced cirrhosis
- D. Chronic pancreatitis
Explanation: ***Renal insufficiency*** - **Digoxin** is primarily excreted unchanged by the **kidneys**, so impaired renal function significantly prolongs its half-life and leads to drug accumulation. - Patients with kidney failure require **dose adjustments** or closer monitoring of **digoxin levels** to prevent toxicity. *Chronic hepatitis* - **Chronic hepatitis** primarily affects the **liver's metabolic capacity**, which is not the primary route of **digoxin elimination**. - While severe hepatic dysfunction can subtly impact drug disposition, it's not the main reason for **digoxin accumulation** like **renal insufficiency**. *Advanced cirrhosis* - **Advanced cirrhosis** involves severe liver dysfunction, which can alter drug metabolism and protein binding. - However, **digoxin's elimination** is mainly renal, so liver disease alone does not typically lead to significant accumulation unless accompanied by **renal impairment**. *Chronic pancreatitis* - **Chronic pancreatitis** is a disorder of the pancreas and does not directly impact the **excretion or metabolism** of **digoxin**. - It would not be expected to cause **digoxin accumulation** to toxic levels.
Question 9: Which of the following is the primary mechanism that drives sodium reabsorption in the proximal tubule?
- A. Sodium reabsorption through cotransport with amino acids at the luminal membrane.
- B. Sodium reabsorption through cotransport with glucose at the luminal membrane.
- C. Sodium reabsorption through countertransport with hydrogen ions at the luminal membrane.
- D. Active sodium transport via the Na+-K+-ATPase pump at the basolateral membrane. (Correct Answer)
Explanation: ***Active sodium transport via the Na+-K+-ATPase pump at the basolateral membrane.*** - This pump **actively transports sodium out of the cell** into the interstitial fluid, creating a low intracellular sodium concentration. - The **Na+-K+-ATPase** is the primary driver of sodium reabsorption throughout the nephron, creating the electrochemical gradient for other sodium transporters. *Sodium reabsorption through cotransport with amino acids at the luminal membrane.* - While **sodium-amino acid cotransport** does occur in the proximal tubule, it accounts for only a fraction of total sodium reabsorption. - The primary driving force for this cotransport is the **low intracellular sodium concentration** maintained by the Na+-K+-ATPase. *Sodium reabsorption through cotransport with glucose at the luminal membrane.* - **Sodium-glucose cotransporters (SGLTs)** are crucial for glucose reabsorption in the proximal tubule, moving glucose into the cell along with sodium. - However, glucose cotransport represents a specific mechanism for glucose handling, not the overarching mechanism for sodium reabsorption. *Sodium reabsorption through countertransport with hydrogen ions at the luminal membrane.* - The **Na+-H+ exchanger (NHE3)** is significant for exchanging sodium for hydrogen ions at the luminal membrane in the proximal tubule. - This mechanism is important for **acid-base balance** and some sodium reabsorption, but it is secondary to the Na+-K+-ATPase in driving the overall sodium gradient.
Question 10: Which of the following DPP-IV inhibitors is safe for use in chronic kidney disease patients without requiring dose modification?
- A. Sitagliptin
- B. Vildagliptin
- C. Linagliptin (Correct Answer)
- D. Saxagliptin
Explanation: ***Linagliptin*** - Unlike other **DPP-IV inhibitors**, **linagliptin** is primarily eliminated via **biliary/fecal excretion** (~85%) rather than renal excretion. - This unique elimination pathway makes it **safe** for use in patients with **chronic kidney disease** at its usual dose, without the need for dose adjustment. - It is the **only DPP-IV inhibitor** that does not require dose modification in CKD. *Sitagliptin* - **Sitagliptin** is primarily eliminated by the **kidneys** (~80% renal excretion), requiring **significant dose adjustments** in patients with **renal impairment**. - Without dose modification, there is an increased risk of **drug accumulation** and adverse effects in CKD patients. *Vildagliptin* - **Vildagliptin** undergoes **hydrolysis** with subsequent **renal excretion** of inactive metabolites, requiring **dose reduction** in patients with moderate to severe **renal impairment**. - Not recommended in severe renal impairment (eGFR <50 mL/min). *Saxagliptin* - **Saxagliptin** is partially eliminated via **renal excretion** and requires **dose reduction** by 50% in patients with moderate to severe **CKD**. - Both parent drug and active metabolite accumulate in renal impairment, necessitating dose adjustment.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free